Diverse expression patterns and tumorigenic role of neurotensin signaling components in colorectal cancer cells

International Journal of Oncology
Ji Tae KimB Mark Evers

Abstract

Colorectal cancer (CRC), which is one of the most common malignancies worldwide, results from an accumulation of genetic and epigenetic modifications including DNA methylation. Neurotensin (NTS), a hormone localized to the gut and central nervous system, mediates its physiological and pathological effects, including growth stimulation for a variety of cancers, through three distinct NTS receptors (NTSRs). Most NTS functions are mediated through the high-affinity receptor NTSR1, and expression of NTSR1 is increased in many cancers including CRC. In this study, we investigated the expression profiles and cellular functions of the NTSRs, especially NTSR1, in CRC cells. We showed that expression levels for NTS and NTSR1 varied, that NTSR2 expression was not detectable and that NTSR3 was consistently expressed in all CRC cell lines examined. Treatment with the demethylating agent, 5-aza-2'-deoxycytidine, augmented levels of NTSR1/2 in Caco2 and DLD1 cells, which have little or no transcripts for NTSR1/2 suggesting that DNA methylation suppresses NTSR1/2 expression. In addition, we demonstrated that knockdown of NTSR1 decreased cell growth and migration in HCT116 and HT29 cells. Finally, we showed that treatment with SR48692, an anta...Continue Reading

References

Oct 11, 1992·Annals of Surgery·B M EversJ C Thompson
Oct 21, 1998·Oncogene·E Kerkhoff, U R Rapp
Nov 30, 2000·American Journal of Physiology. Gastrointestinal and Liver Physiology·Z DongB M Evers
Feb 14, 2003·American Journal of Physiology. Cell Physiology·Dezheng ZhaoCharalabos Pothoulakis
Nov 7, 2006·Neuropathology and Applied Neurobiology·S ServotteC Decaestecker
Jun 6, 2009·Molecular Oncology·Aik Choon TanManuel Hidalgo
Jul 22, 2010·International Journal of Cancer. Journal International Du Cancer·Yan NingHeinz-Josef Lenz
Sep 3, 2010·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Marco AlifanoPatricia Forgez
Nov 26, 2010·Annual Review of Pathology·Eric R Fearon
Dec 3, 2010·Current Opinion in Endocrinology, Diabetes, and Obesity·W Conan MustainB Mark Evers
May 10, 2011·Regulatory Peptides·Konstantinos Kalafatakis, Konstantinos Triantafyllou
Sep 10, 2011·Cancer Research·Nicholas C K ValerieJaroslaw Dziegielewski
Aug 8, 2014·International Journal of Cancer. Journal International Du Cancer·Ji Tae KimB Mark Evers
Jan 7, 2015·CA: a Cancer Journal for Clinicians·Rebecca L SiegelAhmedin Jemal
Jan 13, 2015·Current Colorectal Cancer Reports·Hassan Ashktorab, Hassan Brim

❮ Previous
Next ❯

Citations

Mar 4, 2020·Biochemistry and Cell Biology = Biochimie Et Biologie Cellulaire·Aihua LiuLihua Liu
May 21, 2020·International Journal of Molecular Sciences·Aldona Kasprzak, Agnieszka Adamek
Dec 4, 2020·Cell Death & Disease·Niki ChristouAurélie Perraud
Jan 21, 2021·Cancers·Simone L SchonkerenVeerle Melotte
Sep 6, 2020·Bioconjugate Chemistry·Roberto FanelliFlorine Cavelier
Sep 25, 2021·Cellular and Molecular Gastroenterology and Hepatology·Stephanie A RockB Mark Evers

❮ Previous
Next ❯

Methods Mentioned

BETA
gene knockdown
reverse transcription-PCR
PCR
transfection
Assay

Software Mentioned

NIS Elements

Related Concepts

Related Feeds

Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cancer Epigenetics

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cancer Epigenetics & Methyl-CpG (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. Here is the latest research on cancer epigenetics and methyl-CpG binding proteins including ZBTB38.

Cancer Epigenetics and Senescence (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may be involved in regulating senescence in cancer cells. This feed captures the latest research on cancer epigenetics and senescence.

Cancer Epigenetics & Metabolism (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on the relationship between cell metabolism, epigenetics and tumor differentiation.

Cell Signaling & Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. This feed covers the latest research on signaling and epigenetics in cell growth and cancer.

Cell Migration

Cell migration is involved in a variety of physiological and pathological processes such as embryonic development, cancer metastasis, blood vessel formation and remoulding, tissue regeneration, immune surveillance and inflammation. Here is the latest research.

Cell Migration in Cancer and Metastasis

Migration of cancer cells into surrounding tissue and the vasculature is an initial step in tumor metastasis. Discover the latest research on cell migration in cancer and metastasis here.